Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of pessimism is justified, the current market cap is way to low considering ...

GLP-1 weight loss drugs are still far from cheap, but some of the prices keep dropping. Novo Nordisk is now offering people who pay out of pocket a steep discount for select doses of Ozempic and ...

(Bloomberg) --Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc ...

Editor's note: This article has been updated to provide clarity on a head-to-head study Eli Lilly conducted on its candidate, orforglipron. A pill version under development of Novo Nordisk's (NVO) GLP ...

Novo Holdings, which had 142 billion euros ($165.60 billion) in assets under management by 2024-end, is in talks with several Indian companies, Amit Kakar, managing partner and head of Asia, told ...

Based on the one-year price targets offered by 24 analysts, the average target price for Novo Nordisk AS (OCSE:NOVO B) is $439.74 with a high estimate of $720.00 and a low estimate of $232.00. The ...

Drugmaker Pfizer PFE-1.83%decrease; red down pointing triangle on Friday sued obesity-drug developer Metsera and Novo Nordisk NOVO.B-0.80%decrease; red down pointing triangle, seeking to block Metsera ...

Chairman, six board members to stand down next month Top shareholder proposes new board members Former Novo CEO Sorensen to become chair for 2-3 years Boardroom feud comes in midst of company ...

Pressured by its top shareholder, Novo Nordisk on Tuesday said key board members will be replaced. Pressured by its key shareholder, the Novo Nordisk Foundation, the company said its chairman, Helge ...

Most effective drugs for obesity and its complications are semaglutide, tirzepatide, new European guideline says Certain GLP-1 drugs are best for specific complications The non-binding guideline ...

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too. By Eshe Nelson The success of Novo Nordisk, the ...

Novo Nordisk A/S is working on a strategy to make obesity treatment more personalized and wants to offer options for every kind of patient. The Danish company envisions a trajectory of treatment that ...